文献速递血液净化与透析肾血管病与高血压

降压药治疗与血液透析中低血压风险

Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-07-16

该研究采用模拟随机临床试验方法,纳入4072例新发血液透析患者,比较单药降压治疗与透析中低血压(IDH)风险的关系。以钙通道阻滞剂(CCB)为参照,β及α-β受体阻滞剂、ACEI或ARB、利尿剂均与IDH风险升高相关。

要点

  • 在新发血透患者中,与CCB相比,β及α-β受体阻滞剂与IDH风险升高相关(OR 2.27)。
  • ACEI或ARB(OR 1.71)及利尿剂(OR 1.52)与IDH风险升高相关。
  • CCB的IDH发生率为7.4例/人年(95%CI 6.2-8.6)。

核心结论

  • 与CCB相比,使用β及α-β受体阻滞剂、ACEI或ARB、利尿剂可能增加血透患者IDH风险。

主要发现

  • CCB的IDH发生率为7.4例/人年(95%CI 6.2-8.6)。
  • 与CCB相比,β及α-β受体阻滞剂的IDH风险OR为2.27(95%CI 1.50-3.43)。
  • 与CCB相比,ACEI或ARB的IDH风险OR为1.71(95%CI 1.14-2.57)。
  • 与CCB相比,利尿剂的IDH风险OR为1.52(95%CI 1.07-2.16)。

临床怎么用

  • 血透患者选择降压药时,需权衡IDH风险,CCB可能具有较低风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Antihypertensive medications are often used by hemodialysis patients, and intradialytic hypotension is a common complication in these patients. The study emulates a randomized clinical trial comparing antihypertensive drug treatment for the risk of hemodialysis hypotension in 4072 incident patients. Compared with calcium antagonists, β and α–β blockers, angiotensin converting enzyme inhibitors or angiotensin II antagonists, and diuretics may increase the risk of hemodialysis hypotension. BACKGROUND: Antihypertensive medications are often prescribed to manage hypertension in hemodialysis patients, and intradialytic hypotension (IDH) is a common complication in these patients. We investigated the risk of IDH in incident hemodialysis patients who initiated treatment with antihypertensive drugs in monotherapy. METHODS: The study was conducted as an emulation of a randomized clinical trial in 4072 incident hemodialysis patients who started antihypertensive drug treatment between January 2016 and December 2019. The primary outcome was the occurrence of IDH during hemodialysis sessions. The generalized estimating equation analysis was adjusted by inverse probability treatment weighting. RESULTS: Calcium channel blocker (CCB) use was associated with an IDH incidence rate of 7.4 events per person-year (95% confidence interval [CI], 6.2 to 8.6). Compared with CCB use, use of β and α–β blockers was strongly associated with a higher likelihood of IDH (odds ratio [OR] [95% CI, 2.27; 1.50 to 3.43]). The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (OR [95% CI, 1.71; 1.14 to 2.57]) and diuretics (OR [95% CI, 1.52; 1.07 to 2.16]) were also associated with a higher likelihood of IDH compared with CCB use. CONCLUSIONS: The study suggests that using β and α–β blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and diuretics may increase the risk of IDH in hemodialysis patients compared with CCB use.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zoccali C, Tripepi G, Carioni P, et al. Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension. Clin J Am Soc Nephrol. 2024. PMID: 39012707. doi:10.2215/CJN.0000000000000521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。